4bbx

Publication Abstract from PubMed

We report the discovery of a series of imidazo[1,2-a]pyrazine derivatives as novel inhibitors of phosphodiesterase 10A (PDE10A). In a high throughput screening (HTS) campaign we identified the imidazopyrazine derivative 1, a PDE10A inhibitor with limited selectivity versus the other phosphodiesterases (PDEs). Subsequent investigation of 1 and replacement of the trimethoxyphenyl group by a methoxyethylpyrazole moiety maintained PDE10A inhibition but enhanced selectivity against the other PDEs. Systematic examination and analysis of structure-activity- and structure-properties-relationships (SAR and SPR) resulted in the discovery of 2, an in vitro potent and selective inhibitor of PDE10A with high striatal occupancy of PDE10A, promising in vivo efficacy in different rodent behavioral models of schizophrenia, and good pharmacokinetic profile in rats.

Discovery of a potent, selective and orally active PDE10A inhibitor for the potential treatment of schizophrenia.,Bartolome-Nebreda JM, Delgado F, Martin ML, Martinez-Viturro CM, Pastor J, Tong HM, Iturrino L, Macdonald GJ, Sanderson WE, Megens A, Langlois X, Somers M, Vanhoof G, Conde Ceide S J Med Chem. 2014 Apr 23. PMID:24758746^[2]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.